Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy.
Naoto KuyamaSeiji TakashioTetsuya OguniMasahiro YamamotoKyoko HirakawaMasanobu IshiiShinsuke HanataniSeitaro OdaYasushi MatsuzawaHiroki UsukuEiichiro YamamotoToshinori HiraiMitsuharu UedaKenichi TsujitaPublished in: Journal of the American Heart Association (2024)
Deterioration in cardiac biomarkers during the first year after tafamidis treatment predicted a worse prognosis, suggesting the utility of serial assessment of cardiac biomarkers for monitoring the therapeutic response to tafamidis in patients with wild-type transthyretin amyloid cardiomyopathy.
Keyphrases